• Users Online: 213
  • Print this page
  • Email this page
 
CASE REPORT
Ahead of Print

Hemophagocytic lymphohistiocytosis after ChAdOx1 nCoV-19 coronavirus vaccination in a patient with no known comorbidities


1 Department of Critical Care Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India
2 MBBS Students, Faculty of Medical Sciences, King George's Medical University, Lucknow, Uttar Pradesh, India
3 Department of Pathology, King George's Medical University, Lucknow, Uttar Pradesh, India

Correspondence Address:
Shubhajeet Roy,
Faculty of Medical Sciences, King George's Medical University, Shah Mina Road, Chowk, Lucknow - 226 003, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/injms.injms_80_22

Hemophagocytic lymphohistiocytosis (HLH) is an inflammatory condition where there is marked cytopenia and large-scale activation of macrophages and CD8+ cytotoxic T cells. HLH may be of two types – primary HLH caused by genetic abnormalities and secondary HLH due to infections, malignancies, autoimmune disorders, rheumatologic disorders, and metabolic dysfunctions. We describe a case of HLH following the first dose of the ChAdOx1 nCoV-19 Corona Virus vaccine. In this patient, there was no clear precipitant of HLH. The most probable explanation could be intense immune activation by vaccine constituents producing aberrant activation of inflammatory cytokines. There were no signs of infection or malignancy. Since our patient was clinically stable, his symptoms had resolved and HLH parameters had improved, no HLH-specific therapy was given.


Print this article
Search
 Back
 
  Search Pubmed for
 
    -  Rai N
    -  Misra S
    -  Prajapati S
    -  Roy S
    -  Yadav G
 Citation Manager
 Article Access Statistics
 Reader Comments
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed323    
    PDF Downloaded3    

Recommend this journal